Paper review: ‘switch’ chemotherapy in canine splenic haemangiosarcoma post-splenectomy
This article, published last year, is quite exciting: dealing, as it does, with a common situation in our day to day caseload. It is an oft-quoted statistic that <10% of splenic haemangiosarcoma cases will survive one year from spelnectomy even if no metastases are grossly apparent at the time of surgery and using doxorubicin-based … Continue reading
